

GHIT 3.0 Strategic Plan

FY2023-FY2027

GHIT Fund

Global Health Innovative Technology Fund



A photograph of four children of diverse backgrounds. In the center is a young girl with dark hair and a nose ring, wearing a red patterned dress, smiling broadly. To her left is a boy with a wide smile, and to her right is a girl with long dark hair. In the bottom left corner, another child is partially visible, looking towards the camera. The background is slightly blurred, showing what appears to be a wooden structure. A blue diagonal graphic element is in the top left corner.

VISION

Our vision is a world free of neglected infectious diseases that affect over a billion people with the aim of achieving health equity.

MISSION

We leverage Japanese innovation and leadership to fight against neglected infectious diseases through investing in research and development and promoting global partnerships.

Message from CEO and Chair

Celebrating 10 Years Since Our Founding

In 2023, the Global Health Innovative Technology Fund (GHIT Fund) celebrates its 10th anniversary. We are grateful to our funding partners and sponsors for their support and collaboration over the past decade, to our product development partners for their passion and tireless efforts in the fight against neglected infectious diseases, and to the global health community for its solidarity and partnership.

The concept of the GHIT Fund was born from notes written on a paper napkin by the late Dr. Tachi Yamada and GHIT's founding CEO, Dr. BT Slingsby, in 2013. Since then, we have been fighting neglected diseases in low and middle-income countries by connecting ideas, people, and innovations from around the world. In our experience, passion and vision are more powerful tools than most may realize. Each new drug in development or nearing approval has the potential to save tens of millions of lives.

Cumulative investments over the past 10 years have totaled approximately 30 billion yen, supporting more than 100 R&D projects. More than 50 projects are currently underway, of which 12 are in clinical development. As of April 1, 2023, GHIT's family of active Japanese and global partners is 170-strong, all supporting our mission to connect Japanese pharmaceutical companies and universities with global partner institutions to accelerate global health innovation.

GHIT 3.0 Strategic Plan

In our third phase of operations (FY2023 – FY2027), we will continue to promote the development of therapeutics, vaccines and diagnostics through global collaboration, aiming for greater efficiency and acceleration of R&D than ever before. Our third five-year plan, “GHIT 3.0”, features three strategic pillars: Galvanize Innovation, Catalyze Partnerships and Maximize Impact. The work under these pillars reinforces our role as an

international organization that promotes innovation and product development for neglected diseases prevalent mainly in low and middle-income countries.

Developing new medicines is no easy task, requiring an average of over ten years of painstaking effort and tens of billions of yen to develop a single medicine. But the time and investment are worth it. GHIT's projects, which have been created and nurtured over the past decade, are about to bear fruit. By delivering the therapeutics, vaccines and diagnostics that result from our development partnerships to sick patients as quickly as possible, we will save countless lives and prevent untold suffering and stigma from the complications of neglected diseases.

At the GHIT Fund, we will continue to promote innovation and R&D from Japan and fight neglected infectious diseases through global partnerships. We remain steadfast in our mission to reduce the suffering caused by neglected infectious diseases that afflict more than a billion people, in support of a healthy world for all. We leap into this work together with you, as partners.

We look forward to your continued support and cooperation.



Osamu Kunii
CEO and Executive Director



中谷 比呂樹

Hiroki Nakatani
Board Chair & Representative Director

Value of the GHIT Fund



Japanese Innovation

Improving global health by identifying and investing in Japanese innovation



Global Partnership

Facilitating cross-border & cross-sector partnership to accelerate product development



Support Globalization

Advancing the Globalization of Japan's pharmaceutical industry and reinforcing ESG management

GHIT Product Development Partners

Japanese Organizations **59** Non-Japanese Organizations **111**



■ = Clinical Candidates and GHIT Partners

As of April 1, 2023

Investment Scope

Malaria

247 million

Infected in 2021

619,000

Deaths in 2021



Malaria is caused by a parasite called *Plasmodium* and is transmitted to humans through the bite of a female Anopheles mosquito carrying this parasite. There are five types of parasites which cause malaria in humans, and among these, the *Plasmodium falciparum* and the *Plasmodium vivax* have become a threat.


Tuberculosis

10.6 million

Infected in 2021

1.6 million

Deaths in 2021



Tuberculosis (TB) is one of the 10 leading causes of death globally. It is caused by bacteria (*Mycobacterium tuberculosis*), which most often show symptoms in the lungs, and spread through airborne transmission. TB is the leading cause of death among HIV-positive people. Multidrug-resistant TB (MDR-TB) also remains a public health crisis and a threat to health security.

Neglected Tropical Diseases: NTDs

1.6 billion

Infected in 2021



Neglected Tropical Diseases (NTDs)— a group of 20 communicable diseases prevalent in tropical and subtropical conditions in approximately 150 countries – affect more than one billion people and cost developing economies billions of dollars every year. Populations living in poverty, without adequate sanitation, and in close contact with infectious vectors, domestic animals, and livestock are those worst affected.



Source: World Health Organization (WHO) <https://www.who.int/news/item/30-01-2023-more-countrieseliminate-neglected-tropical-diseases-but-investments-key-to-sustain-progress>

Strategic Plan FY2018-FY2022

Advancement of Investments in R&D and Product Development

Objective	R&D milestone		Targeted by March 2023	Achieved by March 2023	
	Diagnostics	Innovative diagnostics technologies identified and funded	5	▶	11 Achieved
Leverage innovations from Japanese biopharma and academia	Lead Identification	Hit-to-lead programs funded	5	▶	17 Achieved
	Preclinical	Preclinical candidates identified	8	▶	14 Achieved
Advance R&D investment pipeline and prioritize late-stage candidates	Phase I	First-in-human clinical trials conducted	5	▶	6 Achieved
	Phase II - Phase III	Proof of concept achieved	3	▶	4 Achieved
	Registration	Approval from a stringent regulatory authority	2	▶	1

As of March 31, 2023

GHIT Fund has played the pivotal role in promoting research and development to fight neglected diseases by making most of Japanese technology and innovation and promoting global partnership between academia, public and private sector.

Peter Piot, MD, PhD

Professor of Global Health,
London School of
Hygiene & Tropical Medicine
Special Advisor on COVID-19
to the President of the
European Commission



At the end of 2022, the European Medicines Agency validated our application and started the scientific review process for the potential new pediatric treatment option for schistosomiasis. Having reached this milestone after more than 10 years of intense and collaborative work makes me very proud.

Dr. Jutta Reinhard-Rupp

Chair of the Pediatric
Praziquantel Consortium
Board Head of the Global
Health Institute at Merck



GHIT's achievements are not limited to promoting research and development, but also include contributing to the globalization and human resource development of researchers in the field of infectious diseases in Japan. I believe that GHIT's unique investment in joint research between Japanese and foreign organizations further strengthens the research capabilities and partnerships of Japanese research institutions.

Prof. Kiyoshi Kita

Dean, Graduate School of
Tropical Medicine and Global
Health, Nagasaki University




GHIT 3.0 Strategic Plan

Galvanize Innovation

Accelerate Late-Stage Product Development

Strategic Plan FY2023-FY2027



Promote Open, Collaborative R&D



- Co-creation of products through international joint research and transparency in sharing findings between various industries of academia, research institutes, pharmaceutical companies, SMEs and Japanese and international startups.

GHIT 3.0 Strategic Plan

Maximize Impact

Optimize Portfolio

GHIT 1.0

FY2013-FY2017



Phase I: Creation

- Establish an innovative funding mechanism to create international public goods from Japan through public-private partnership (Japanese government × private companies × foundations).
- Launch R&D projects utilizing Japanese drug discovery technologies and innovations.

GHIT 2.0

FY2018-FY2022



Phase II: Growth

- Advance product development pipelines through active management of existing portfolio alongside proactive new investments in innovative technologies applicable to global health.
- Support access and delivery through close collaboration with international organizations.

GHIT 3.0


FY2023-FY2027



Phase III: Harvest

- Accelerate product development for malaria, tuberculosis and NTDs.
- Optimize portfolio and resources to maximize the investment impact and further strengthen institutional development.
- Foster and promote domestic and international partnerships aimed at sparking innovation.

Leverage Resources



- Continue to leverage limited resources by exploring various funding mechanisms and prioritizing sustainability.

Enhance Governance and Institutional Management




- Further enhance corporate governance and institutional development.
- Ensure organizational sustainability through deployment of appropriate HR management and financial strategies.

GHIT 3.0 Strategic Plan

Catalyze Partnerships

Create an Enabling Environment for Access & Delivery

GHIT works proactively with product development partners to help them develop robust launch strategies and establish strategic, product-focused partnerships for appropriate, timely access and delivery of their innovations. Key considerations are illustrated below.



GHIT facilitates strategic partnerships for Access and Delivery



Top-down approach:

Create a platform for aligned action across the innovation-access-delivery continuum.



Bottom-up approach:

Ensure launch strategies for GHIT-invested clinical candidates

Strengthen Strategic Partnerships, Focusing on LICs & LMICs



- Continue to extend institutional presence in LICs and LMICs and explore innovations from the ground up.

Demonstrate End-to-End R&D/A&D Ecosystems



- Leverage UNDP and other global networks to ensure seamless connectivity between innovation (R&D) and access and delivery (A&D).

Leadership

Council

Composed of representatives of the Japanese government, global foundations and private companies which contribute funding, GHIT's Council votes on important affairs, such as the election and dismissal of governors, amendments to the articles of incorporation, and the approval of financial statements.



Takeshi Akahori

Ambassador, Director-General for Global Issues
Ministry of Foreign Affairs



Eiji Hinoshita, MD, Ph.D, MSc.

Assistant Minister for Global Health and Welfare
Ministry of Health, Labour and Welfare



Trevor Mundel, MD, PhD

President, Global Health
Bill & Melinda Gates Foundation



Cheryl Moore

Chief Research Programmes Officer
Wellcome



Astellas Pharma Inc.

Kenji Yasukawa
Representative Director,
Chairman of the Board



Chugai Pharmaceutical Co., Ltd.

Osamu Okuda, PhD
Representative Director, President & CEO



Daiichi Sankyo Company, Limited

Sunao Manabe, Ph.D
Representative Director,
Executive Chairperson & CEO



Eisai Co., Ltd.

Haruo Naito
Representative Corporate Officer
and CEO



Shionogi & Co., Ltd.

Isao Teshirogi, PhD
Representative Director,
President and CEO



Takeda Pharmaceutical Company Limited

Christophe Weber
Representative Director
President and CEO

Board of Directors

Composed of global health and management experts, GHIT's Board of Directors oversees the work of the leadership team and votes on important affairs related to business management, such as the approval of important regulations, mid-term strategies, annual plans, budgets, and investment opportunities.



Chair & Representative Director
Hiroki Nakatani, MD, PhD, MHPed
Visiting Professor
Keio University School of Medicine



Vice Chair
Peter Piot, MD, PhD

Professor of Global Health, London School of Hygiene & Tropical Medicine
Special Advisor on COVID-19 to the President of the European Commission



Executive Director
Osamu Kunii, MD, PhD, MPH
CEO, GHIT Fund



Mahima Datla

Managing Director
Biological E. Limited



Satoshi Ezoe, MD, MPH, MPA, PhD

Director, Global Health Policy Division
International Cooperation Bureau
Ministry of Foreign Affairs



Tetsuya Itani

Director
Office of Global Health Cooperation
Ministry of Health, Labour and Welfare



Daikichi Momma

Vice Chairman
Institute for International Economic Studies



Ann M. Veneman, JD

Former Executive Director, UNICEF
Former Secretary
United States Department of Agriculture



Supervisory Board Member
Hikaru Ishiguro, LLM

Statutory Auditor
INSPIRE Corporation



Supervisory Board Member
Saori Nakamura

Attorney at Law
Hirayama Nagareya Shirai Law Office



Supervisory Board Member
Ko-Yung Tung, JD

Lecturer on Law, Harvard Law School,
Former Senior Vice President
and General Counsel, World Bank



Ex-Officio
Katey Einterz Owen, PhD

Director, Neglected Tropical Diseases
Pharmaceutical Industry Leadership
Engagement
Bill & Melinda Gates Foundation



Ex-Officio
Richard Seabrook, PhD, MBA

Independent Senior Advisor, Innovations,
Wellcome CEO 360Biomedical Ltd
Royal Society Entrepreneur in Residence University of Bristol

Leadership

Selection Committee

Composed of domestic and foreign experts with a wealth of knowledge and experience in R&D of therapeutic agents, vaccines, and diagnostic agents, the Selection Committee (SC) examines and evaluates applications and progress reports from program applicants and recommends investment opportunities to the Board of Directors. To avoid any conflict of interest between our backers and development partners, the SC does not include private sector representatives.



Co-Chair
Ann Mills-Duggan, PhD
Independent Consultant



Co-Chair
Naoto Uemura, MD, PhD
Professor, Department of Clinical
Pharmacology and Therapeutics
Oita University Faculty of Medicine



Ralf Clemens, MD, PhD
Independent Vaccine Expert



Ken Duncan, PhD
Deputy Director
Discovery & Translational Sciences
Bill & Melinda Gates Foundation



Ken Ishii, MD, PhD
Professor, Institute of Medical Science
University of Tokyo



Timothy Jinks, PhD
Head, Infectious Diseases Interventions
Wellcome



Hiroo Koyama, PhD
Platform Unit Leader
Drug Discovery Chemistry Platform Unit
RIKEN Center for Sustainable Resource Science



Karen L. Menge, PhD
Independent Consultant



Dennis Schmatz, PhD
Former Vice President of R&D,
Merck Research Labs, USA
Former Site Head - Merck Research
Labs, Japan



Anna-Karin Tidén, PhD, MRSC
Independent Medicinal Chemistry Expert



Rieko Yajima, PhD
Director, Drug Discovery Innovation
SPARK Program in Translational Research
Stanford University School of Medicine

Leadership Team

The leadership team facilitates the development of business, investment, and organizational growth strategies, executes strategies based on the approval of the Board of Directors, and implements administrative tasks.



Osamu Kunii, MD, PhD, MPH
CEO



Kei Katsuno, MD, MPH
Senior Director, Investment Strategy
Business Development



Eriko Mugitani
Associate Director,
Brand Communications



Shin Sakai
Associate Vice President,
Corporate Operations



Kazue Seki
Director, External Affairs &
Corporate Development



Miho Takazawa, MBA
Senior Director, Finance & Operations



Hayato Urabe, PhD, MPIA
Associate Vice President, Investment Strategy
Portfolio Development & Innovations

Funding Partners and Sponsors

GHIT Fund is a Japan-based global public-private partnership fund for global health R&D. We invest in nonprofit product development for malaria, tuberculosis, and Neglected Tropical Diseases (NTDs). GHIT's sponsor companies provide in-kind services in support of GHIT's mission.





















Government

Full Partners			
	外務省 MOFA Japan Ministry of Foreign Affairs	厚生労働省 Ministry of Health, Labour and Welfare	United Nations Development Programme

Foundation

Full Partners		
	Bill & Melinda Gates Foundation	Wellcome

Private Companies

Full Partners						
	Astellas Pharma Inc.	Chugai Pharmaceutical Co., Ltd.	Daiichi Sankyo Co., Ltd.	Eisai Co., Ltd.	Shionogi & Co., Ltd.	Takeda Pharmaceutical Company Limited
Associate Partners						
	FUJIFILM Corporation	Fujirebio Holdings, Inc.	Otsuka Pharmaceutical Co., Ltd.			
Affiliate Partners						
	Kyowa Kirin Co., Ltd.	Merck KGaA	Mitsubishi Tanabe Pharma Corporation	Sumitomo Pharma Co., Ltd.		
Sponsors						
	Burson Cohn & Wolfe Japan Inc.	Diligent Japan Ltd.	Linkties Co., Ltd.	Mori Building Co., Ltd.	Morrison & Foerster LLP	Salesforce Japan Co., Ltd.
						
	ZVC JAPAN K.K.					

As of August 31, 2023

As of August 31, 2023